|Last Update: 05/17/13 - 4:00 PM EDT|
|YTD Performance: 15.86%|
|Previous Close: $62.14|
|52 Week Range: $50.32 - $63.95|
|Oustanding Shares: 1,020,007,037|
|Market Cap: 63,383,237,279|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||12||12||14||14|
|Growth Rate (Year over Year)||-0.79%||2.61%||3.07%||7.39%|
Today definitely did no real damage to the intermediate-term trend.
Its chart tells us that it's positioned to catch up to its peers.
The biggest, most-important, most-visible companies have done poorly.
UNH earnings estimates through 2014 were reduced for sequestration and a more cautious MA outlook, said UBS.
Book profits, don't chase strength.
Upward momentum is lagging.
Shares of UNH now seen reaching $71, according to Credit Suisse. PBM business is not being appreciated by investors. Outperform rating.
UNH was initiated with a Buy rating, said UBS. The company's scale, cash flow and growth in the Optum business will drive upside to shares. Price target is $72.
Health Insurance names are leading a market rebound. Portfolio Manager David Peltier highlights Tuesday's early movers.
Worse-than-expected ISM report contributed to market weakness.